Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector – Amino acid sequence disclosed in whole or in part; or...
Reexamination Certificate
2007-09-11
2007-09-11
Chan, Christina (Department: 1644)
Drug, bio-affecting and body treating compositions
Antigen, epitope, or other immunospecific immunoeffector
Amino acid sequence disclosed in whole or in part; or...
C424S278100, C514S002600, C514S005200, C514S724000, C530S328000, C530S345000, C530S402000
Reexamination Certificate
active
10780321
ABSTRACT:
Novel oligonucleotides comprising a sequence derived by a computer program are provided for inhibiting cytotoxic activity of lymphocytic cells, inhibiting production of inflammatory cytokines and inflammatory responses associated with those cytokines, inhibiting the activity of heme-containing enzymes and delaying the onset of an autoimmune disease. By combining the subject compositions with mixtures of cells comprising lymphocytic cells and cells which would otherwise activate the lymphocytic cells, lysis of the target cells can be substantially inhibited. The oligopeptides may be joined to a variety of other groups or compounds for varying the activity of the subject composition. The subject compositions may be administered by any convenient means to inhibit lymphocytic attack on tissue, particularly involved with xenogeneic or allogeneic transplants or to inhibit the production of inflammatory cytokines and inflammatory responses associated therewith. The subject compositions may also be used in the inhibition of the activity of heme-containing enzymes.
REFERENCES:
patent: 5385888 (1995-01-01), Goodenow et al.
patent: 5702946 (1997-12-01), Doerschuk et al.
patent: 5723128 (1998-03-01), Clayberger et al.
patent: 5753625 (1998-05-01), Buelow
patent: 6162434 (2000-12-01), Buelow et al.
patent: 6696545 (2004-02-01), Buelow et al.
patent: 6828415 (2004-12-01), Engel et al.
patent: WO88/05784 (1988-08-01), None
patent: WO90/10016 (1990-09-01), None
patent: WO93/03764 (1993-03-01), None
patent: WO93/08817 (1993-05-01), None
patent: WO93/17699 (1993-09-01), None
patent: WO94/02162 (1994-02-01), None
patent: WO95/13288 (1995-05-01), None
patent: WO96/22306 (1996-07-01), None
patent: WO96/35443 (1996-11-01), None
patent: WO97/24140 (1997-07-01), None
patent: WO97/44052 (1997-11-01), None
patent: WO97/44351 (1997-11-01), None
Abraham, R.J., et al., “Charge Calculations in Molecular Mechanics 7: Application to Polar Pi Systems Incorporating Nitro, Cyano, Amino, C=S and Thio Substituents,”J. Comput. Aided Molec. Des.3(2):175-187 (1989).
Ashton, M.J., et al., “New perspectives in lead generation II: Evaluating molecular diversity,”Disease Drug Ther.1(2):71-78 (Feb. 1996).
Bjorkman, P.J., et al., “Structure of the Human Class I Histocompatibility Antigen, HLA-A2,”Nature329(6139):506-512 (Oct. 1987).
Blaese, R.M., et al., “Gene therapy for primary immunodeficiency disease,”Immunodef. Rev.3(4):329-349 (Jan. 1992).
Buelow, R., et al., “Immunomodulation by soluble HLA class I,”Transplantation59:649-654 (Mar. 1995).
Buelow, R., et al., “Prolongation of Skin Allograft Survival in Mice Following Administration of ALLOTRAP,”Transplantation59(4):455-460 (Feb. 1995).
Cantoni, L., et al., “Interleukin-1 and tumor necrosis factor induce hepatic haem oxygenase. Feedback regulation by glucocorticoids,”Biochem. J.279(3):891-894 (Nov. 1991).
Cuturi, M.C., et al., “Prolongation of allogenic heart graft survival in rats by administration of a peptide (a.a. 75-84) from the α 1 helix of the first domain of HLA-B7 01,”Transplantation59(5):661-669 (Mar. 1995).
Dal Porto, J., et al., “A soluble divalent class I major histocompatibility complex molecule inhibits alloreactive T cells at nanomolar concentrations,”Proc. Natl Acad. Sci. USA90(14):6671-6675 (Jul. 1993).
Fukuda, Y., et al., “Effect of interleukin-11 on the levels of MRNAs encoding heme oxygenase and haptoglobin in human HepG2 hepatoma cells,”Biochem. Biopphys. Res. Commun.193(1):297-302 (1993).
Gao, L., et al., “Both L—and D-isomers of allotrap 2702 prolong cardiac allograft survival in mice,”J. Heart Lung Transplant.15(1):78-87 (Jan. 1996).
Grassy, G., et al., “Computer-assited rational design of immunosuppressive compounds,”Nat. Biotechnol.16(8):748-752 (Aug. 1998).
Grassy, G., et al., “Variable mapping of structure-activity relationships: application to 17-spirolactone derivatives with mineralocorticoid activity,”J. Mol. Graphics13(6):356-367 (Dec. 1995).
Haiech, J., et al., “Use of TSAR as a new tool to analyze the molecular dynamics trajectories of proteins,”J. Mol. Graphics13(1):46-48 (Feb. 1995).
Iyer, S., et al., “Characterization and biological significance of immunosuppressive peptide D2702.75-84(E->V) binding protein,”J. Biol. Chem.273(5):2692-2697 (Jan. 1998).
Kabat, et al., “Sequences of Proteins of Immunological Interest,” NIH publication No. 91-3242, 1:738-740, 770-771, 779-780, 788-789, and 802-804 (1991).
Manolios, N., et al., “T-cell antigen receptor transmembrane peptides modulate T-cell function and T cell-mediated disease,”Nature Med.3(1):84-88 (Jan. 1997).
Ngo, et al., “The Protein Folding Problem and Tertiary Structure Prediction,” K. Merz, Jr., and S. LeGrand (eds.), Birkhauser: Boston, MA, 491-495 (1994).
Nisco, S., et al., “Induction of Allograft Tolerance in Rats by an HLA Class-I-derived Peptide and Cyclosporine A,”J. Immunol.152(8):3786-3792 (Apr. 1994).
Pringle, J.H., (Direct Submission), NCBI Accession No. A38244 (GI2294842), Apr. 14, 1994.
Stagsted, J., et al., “Regulation of insulin receptor functions by a peptide derived from a major histocompatibility complex class I antigen,”Cell62(2):297-307 (Jul. 1990).
Tufveson, G., et al., “New immunosuppressants: testing and development in animal models and the clinic: with special reference to DSG,”Immunol. Rev.136:99-109 (Dec. 1993).
Viswanadhan, V., et al., “Atomic Physicochemical Parameters for Three Dimensional Structure Directed Quantitative Structure—Activity Relationships. 4. Additional Parameters for Hydrophobic and Dispersive Interactions and Their Application for an Automated Superposition of Certain Naturally Occuring Nucleoside Antibiotics,”J. Chem. Inf. Comput. Sci.29(3):163-171 (1989).
Willis, D., et al., “Heme oxygenase: a novel target for the modulation of the inflammatory response,”Nat. Med.2(1):87-90 (Jan. 1996).
Yasri, A., et al., “Rational choice of molecular dynamics simulation parameters through the use of the three-dimensional autocorrelation method: application to calmodulin flexibility study,”Protein Eng.9(11):959-976 (Nov. 1996).
Buelow Roland
Calas Bernard
Grassy Gérard
Chan Christina
DiBrino Marianne
Dorsey & Whitney LLP.
Genzyme Corporation
Lorenz Todd A.
LandOfFree
Cytomodulating lipophilic peptides for modulating immune... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Cytomodulating lipophilic peptides for modulating immune..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Cytomodulating lipophilic peptides for modulating immune... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3759933